Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Core Insights - Ernexa Therapeutics presented new data on engineered cell therapies for ovarian cancer at the AACR Annual Meeting 2025, highlighting the potential of these therapies to enhance immune response and shrink tumors [1][4]. Company Overview - Ernexa Therapeutics (Nasdaq: ERNA) focuses on developing innovative cell therapies for advanced solid tumors and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) transformed into induced mesenchymal stem cells (iMSCs) [5][6]. - The company’s lead product, ERNA-101, aims to activate and regulate the immune system's response against cancer cells, specifically targeting ovarian cancer [6]. Research Findings - The study demonstrated that iMSCs significantly slowed tumor growth and improved survival rates in mice with ovarian cancer, increasing the presence of immune cells such as T cells, natural killer (NK) cells, and macrophages [3]. - iMSCs were shown to enhance T cell growth and multiplication, even in drug-resistant cancer cases, outperforming traditional MSCs in these aspects [3]. Future Implications - The findings suggest that ERNA-101 could represent a more effective, accessible, and scalable treatment option for cancer patients, reinforcing Ernexa's commitment to advancing cancer therapies [4].